BMYBristol-Myers SquibbRunning, no new patients
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
Relapsed or Refractory Multiple Myeloma
3Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Worry score3
Score over time
- Stage
- Phase 3
- Patients
- 606 (final count)
- Started
- Jan 10, 2023
- Main results expected
- Sep 28, 2026
- Fully finished
- Jul 25, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free Survival (PFS)
Measured over: Up to approximately 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05552976 · record last updated 2026-09-24 · checked 2026-11-09 15:47 UTC